Literature DB >> 20320776

OBSERVATIONS UPON THE EXPERIMENTAL AND CLINICAL USE OF SULPHANILAMIDE IN THE TREATMENT OF CERTAIN INFECTIONS.

P H Long1, E A Bliss.   

Abstract

Entities:  

Year:  1937        PMID： 20320776      PMCID： PMC538298     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  9 in total

1.  The treatment of certain experimental anaerobic infections with sulphapyridine and with immune sera and the problem of synergic action.

Authors:  D W Henderson; P A Gorer
Journal:  J Hyg (Lond)       Date:  1940-05

2.  Prevention of Gas-gangrene Infections by Local Application of Sulphonamide Compounds and by Sera.

Authors:  F Hawking
Journal:  Br Med J       Date:  1941-02-22

3.  Chemotherapy of Cl. welchii Type A and Cl. septique Infections in Mice.

Authors:  D Stephenson; H E Ross
Journal:  Br Med J       Date:  1940-03-23

4.  Sulphonamide Treatment of Acute Mastoiditis.

Authors:  V G Horan; S G French
Journal:  Br Med J       Date:  1938-11-05

5.  Chemotherapy by Sulphanilamide Drugs.

Authors:  C H Browning
Journal:  Br Med J       Date:  1939-08-05

6.  TREATMENT OF GAS GANGRENE INFECTIONS IN GUINEA-PIGS WITH NEOPRONTOSIL, SULFANILAMIDE, AND SULFAPYRIDINE: AN EXPERIMENTAL STUDY.

Authors:  D B Kendrick
Journal:  J Clin Invest       Date:  1939-09       Impact factor: 14.808

7.  The Value of Antitoxin in the Prevention and Treatment of Malignant Edema and Gas Gangrene : A Review of Observations.

Authors:  I C Hall
Journal:  Ann Surg       Date:  1945-08       Impact factor: 12.969

8.  Recent Researches on Arthritis and Rheumatism in the United States.

Authors:  P S Hench
Journal:  Ann Rheum Dis       Date:  1939-05       Impact factor: 19.103

9.  Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review.

Authors:  Brad Spellberg; Henry F Chambers; Daniel M Musher; Thomas L Walsh; Arnold S Bayer
Journal:  JAMA Intern Med       Date:  2020-05-01       Impact factor: 21.873
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.